Argus Cognitive has won FDA 510(k) clearance for Neurora, AI software that scores video and audio from a standard behavioral assessment to support autism diagnosis in children from 18 months to 12 years old. The Hanover, New Hampshire company announced the clearance on 8 October 2026, pitching the tool as a second, quantitative opinion for clinicians — not a replacement for one.
Neurora's clearance in four figures
Figures from Argus Cognitive's 8 October 2026 announcement.
From a 2016 Hanover startup to a Class II clearance
Neurora's path to clearance
- 2016
Argus Cognitive founded
Founded in Hanover, New Hampshire, building software medical devices that analyze video and audio data to quantify patient-level function.
- Before clearance
NIH SBIR-backed research
Development of Neurora's underlying behavioral-biometric approach was supported in part by a National Institutes of Health Small Business Innovation Research grant, with earlier findings published in Frontiers in Psychiatry.
- 8 October 2026
FDA 510(k) clearance
FDA clears Neurora, under 510(k) K260064, as a Class II software aid to autism diagnosis in children 18 months through 12 years old.
- Ahead
Clinical rollout
Argus Cognitive has not published a commercial launch timeline or pricing for Neurora since the clearance.
A hundred biometrics, one video upload
Argus Cognitive did not build a new exam; it built a scoring layer for one clinicians already run. A clinician records video and audio during a standard behavioral assessment, uploads it, and Neurora's AI measures more than 100 vocal, facial and gaze biometrics — the pacing of speech, the direction and duration of a child's gaze, facial expressions during specific prompts — and compares the pattern against reference data drawn from children with and without autism. The company positions this as quantitative support for a diagnostic process that has historically relied heavily on a clinician's subjective observation.
That framing matters for how the clearance should be read. Argus Cognitive and the coverage of its clearance are explicit that Neurora's output is meant for interpretation alongside a clinician's other findings and professional judgment — not as a standalone diagnosis. FDA's 510(k) pathway, used here, clears a device as substantially equivalent to a predicate on safety and effectiveness grounds; it does not certify diagnostic accuracy at the level a PMA approval would require, and no accuracy or validation figures for Neurora appeared in the sources reviewed for this article.
“Our goal is to reinforce every diagnosis with robust, quantitative evidence.” Attila Meretei, MD, Chief Executive Officer and co-founder, Argus Cognitive — 8 October 2026 announcement
Three things that shape how Neurora gets used
Built on an exam clinicians already run
Neurora scores a standard behavioral assessment a clinician would conduct anyway, rather than requiring new hardware like the eye-tracking rig a competing tool uses — potentially easing adoption in clinics that already run such exams.
An adjunct, not a verdict
The company frames Neurora's output as a second, quantitative opinion to sit beside clinical judgment, not a standalone diagnostic — a narrower claim than a device seeking to replace clinician assessment outright.
NIH-backed development
The underlying biometric-scoring research was supported in part by a National Institutes of Health Small Business Innovation Research grant, with earlier findings published in a peer-reviewed journal, Frontiers in Psychiatry.
What a hundred-biometric score can't do alone
Autism evaluation already strains clinical capacity: long waits for a developmental-pediatrics or psychology appointment are a well-documented bottleneck to early diagnosis in the United States, which is the market every digital autism-diagnosis aid is implicitly built to address. Neurora does not shorten that wait by itself — a clinician still has to administer the underlying assessment and upload the recording — but it adds a quantitative layer to a process that has otherwise depended on an individual clinician's training and judgment.
The exam room Neurora is entering
$3.44B → $5.03B
Global autism diagnostic market, 2025 to 2034, as forecast by ResearchAndMarkets.
Sources: ResearchAndMarkets, Autism Diagnostic Market Report (via Business Wire, July 2025)
Regulatory News outlook
We expect AI biometric aids like Neurora to take a small but growing share of this market as a second opinion alongside standard behavioral assessments, genetic testing and neuroimaging — not a replacement for them, given FDA's adjunct-only clearance language.
How we got here: ResearchAndMarkets' published 5.6% compound annual growth rate on its $3.44 billion 2025 baseline reaches $5.03 billion by 2034, the publisher's own figure; we treat software-only diagnostic aids as capturing a minority of that total, since the market also includes genetic testing, neuroimaging and in-person developmental screening that a video-scoring tool does not replace.
Neurora against the other biometric aids
| Product | Approach | Age range | US status |
|---|---|---|---|
| Neurora (Argus Cognitive) | AI scoring of video/audio from a standard assessment (100+ biometrics) | 18 months–12 years | FDA cleared, Oct 2026 (K260064) |
| Canvas Dx (Cognoa) | Mobile app; caregiver and clinician questionnaires plus home video | 18 months–5 years | FDA De Novo cleared, 2021 |
| EarliPoint Evaluation (EarliTec Diagnostics) | Dedicated eye-tracking hardware during short videos | 16–30 months | FDA 510(k) cleared, June 2022 |
From each company’s own labelling and FDA clearance announcements; not a clinical comparison.
What a second opinion still needs
Argus Cognitive has not published independent validation data, a price, or a commercial rollout timeline for Neurora since the clearance, and this article has not independently confirmed the K260064 number against FDA's public 510(k) database, which can lag a fresh clearance by days. How clinics adopt a third biometric-scoring entrant — alongside Cognoa's and EarliTec's already-cleared tools, both aimed at overlapping but not identical age ranges — will depend on evidence this announcement does not yet provide.
- Validation data: no published sensitivity, specificity or accuracy figures for Neurora appeared in the sources reviewed for this article.
- Commercial terms: Argus Cognitive has not disclosed pricing, reimbursement coding, or a launch timeline for Neurora since the 8 October 2026 clearance.
- FDA record: the 510(k) number K260064 is as stated in the company's own announcement; Regulatory News will update this page once it is independently confirmed in FDA's public database.
- Competitive field: Cognoa's Canvas Dx and EarliTec's EarliPoint Evaluation were cleared years earlier for overlapping but not identical age ranges, using different data sources.
Sources & further reading
- Argus Cognitive, “FDA Clears Argus Cognitive's Neurora to Support Autism Diagnosis in Children Ages 18 Months Through 12 Years,” press release (Business Wire), 8 October 2026. finance.yahoo.com
- Medical Device Network, “Argus Cognitive's paediatric autism diagnostic secures FDA clearance,” 8 October 2026. medicaldevice-network.com
- Becker's Behavioral Health, “FDA clears autism assessment tool for children,” 8 October 2026. beckersbehavioralhealth.com
- Le Lezard, syndicated copy of the Argus Cognitive Neurora FDA clearance announcement, 8 October 2026. lelezard.com
- MobiHealthNews, “Cognoa's AI app for diagnosing childhood autism gets FDA green light,” 2021. mobihealthnews.com
- BioSpace, “EarliTec Diagnostics Receives FDA 510(k) Clearance for the EarliPoint Evaluation for Autism Spectrum Disorder,” June 2022. biospace.com
- ResearchAndMarkets, Autism Spectrum Disorder Diagnostics — Global market report, via Business Wire, July 2025. researchandmarkets.com
Regulatory News reports on public regulatory documents. It is not legal advice, and the primary sources above govern. If we have made an error, we will say so in public: see corrections.
Frequently asked questions
What did FDA clear for Argus Cognitive?
Neurora, a Class II software as a medical device (SaMD) that analyzes video and audio from a standard behavioral assessment to support autism diagnosis in children ages 18 months through 12 years. FDA cleared it under 510(k) number K260064, as stated in the company's 8 October 2026 announcement; Regulatory News has not independently verified that number against FDA's public 510(k) database, which can lag a clearance by days.
Can Neurora diagnose autism on its own?
No. The company says Neurora's results are intended for interpretation alongside a clinician's other findings and professional judgment, not as a standalone diagnosis.
How does Neurora work?
Clinicians upload video and audio recorded during a standard behavioral assessment. The software measures more than 100 vocal, facial and gaze biometrics and compares them with reference patterns drawn from children with and without autism.
Is Neurora the first AI tool cleared for autism diagnosis?
No. FDA cleared Cognoa's Canvas Dx via De Novo in 2021 (ages 18 months to 5 years) and EarliTec Diagnostics' EarliPoint Evaluation via 510(k) in June 2022 (ages 16 to 30 months). Neurora is a later entrant using a different data source — biometric scoring of a standard assessment video, rather than a caregiver questionnaire or dedicated eye-tracking hardware.
